Insider Selling: OraSure Technologies, Inc. (OSUR) CEO Sells 25,000 Shares of Stock
OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Douglas A. Michels sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the transaction, the chief executive officer now directly owns 743,058 shares of the company’s stock, valued at $16,755,957.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
OraSure Technologies, Inc. (NASDAQ:OSUR) traded down 0.18% during trading on Tuesday, reaching $22.77. The company had a trading volume of 750,850 shares. The firm has a 50-day moving average of $21.34 and a 200-day moving average of $16.97. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 42.09 and a beta of 1.55. OraSure Technologies, Inc. has a 1-year low of $7.09 and a 1-year high of $22.99.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. OraSure Technologies’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period last year, the firm posted $0.07 EPS. On average, analysts anticipate that OraSure Technologies, Inc. will post $0.48 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: OraSure Technologies, Inc. (OSUR) CEO Sells 25,000 Shares of Stock” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/03/insider-selling-orasure-technologies-inc-osur-ceo-sells-25000-shares-of-stock.html.
A number of equities research analysts have recently commented on OSUR shares. Canaccord Genuity raised their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Wednesday, September 20th. Jefferies Group LLC reiterated a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research note on Tuesday, September 12th. BidaskClub cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Finally, Stephens reissued an “overweight” rating and set a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $18.04.
Several hedge funds have recently added to or reduced their stakes in OSUR. Alps Advisors Inc. boosted its holdings in shares of OraSure Technologies by 0.3% in the second quarter. Alps Advisors Inc. now owns 43,257 shares of the medical instruments supplier’s stock valued at $747,000 after acquiring an additional 111 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of OraSure Technologies by 0.5% during the first quarter. PNC Financial Services Group Inc. now owns 46,588 shares of the medical instruments supplier’s stock worth $602,000 after acquiring an additional 242 shares during the period. Profund Advisors LLC raised its holdings in OraSure Technologies by 2.8% during the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 293 shares in the last quarter. Timber Hill LLC raised its holdings in OraSure Technologies by 3.2% during the second quarter. Timber Hill LLC now owns 11,597 shares of the medical instruments supplier’s stock worth $200,000 after purchasing an additional 363 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in OraSure Technologies by 0.5% during the first quarter. Wellington Management Group LLP now owns 111,970 shares of the medical instruments supplier’s stock worth $1,448,000 after purchasing an additional 587 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.